Citigroup maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $22 from $32
Citigroup kept its Buy rating on Ultragenyx Pharmaceutical but reduced its price target from $32 to $22, a 31.2% cut. The new target suggests a 41.3% upside from the Nov 5 close of $15.57. Recent analyst price targets for the company range from $17 to $34.
How this was made

The 30-second read
Why it matters
Analyst downgrade may prompt short‑term price decline.
Market read
Target reduction is a fresh analyst action that could influence trading decisions on ULGN.
What to watch
Potential pipeline milestones not reflected in the target change.
Background
Ultragenyx is a rare‑disease biotech with recent FDA filings.
Market effects
May weigh on other biotech stocks as analysts reassess valuations.
Limited to US biotech sector.
Low global impact.
Counterpoint
Target cut could be overdone if upcoming trial data exceeds expectations.
Key entities
- AnalystCitigroup
Maintained Buy rating but cut price target.
- CompanyUltragenyx Pharmaceutical
Subject of the price‑target revision.

